Keros Therapeutics Narrows Focus on Rinvatercept as Financials Improve
Event summary
- Keros reported net income of $87.0M for 2025, reversing a $187.4M loss in 2024, driven by Takeda license revenue.
- Phase 2 trial for rinvatercept in Duchenne muscular dystrophy (DMD) expected to begin in Q2 2026.
- ALS Phase 2 trial design discussions with regulators planned for second half of 2026.
- Cash position dropped to $287.4M from $559.9M due to share repurchases, with runway into first half of 2028.
The big picture
Keros is sharpening its focus on rinvatercept after a strategic transition period, leveraging Takeda's license revenue to improve financials. The shift reflects a broader industry trend of biotech companies prioritizing high-potential candidates amid tightening capital markets. The company's ability to execute on clinical milestones will be key to maintaining investor confidence and securing future funding.
What we're watching
- Clinical Execution
- Whether Keros can successfully initiate and complete the Phase 2 DMD trial in 2026, a critical step for rinvatercept's development.
- Regulatory Dynamics
- The pace at which ALS trial design discussions progress and potential regulatory hurdles that may arise.
- Financial Sustainability
- How long the current cash position will last given planned operating expenses and whether additional funding will be required before 2028.